All In Biotech

Drug Trial Radar · NCT02256969

Intraductal Meibomian Gland Probing Trial

Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction

Last checked: Nov 20, 2026Latest source record: Jun 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Oct 2014

Primary completion

Aug 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Joseph B. Ciolino, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms. The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.

Conditions

  • Meibomian Gland Dysfunction

Interventions

  • BlephamideDrug

  • GenTeal PM Night-TimeDrug

  • Meibomian Gland ProbingProcedure

    For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.

  • Sham Meibomian Gland ProbingProcedure

    For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Surface Disease Index (OSDI)Time frame: 4 week Time Point
  2. Symptom Assessment in Dry Eye (SANDE)Time frame: 4 week Time Point
  3. Corneal Fluorescein Staining (CFS)Time frame: 4 week Time Point
  4. Tear Break Up Time (TBUT)Time frame: 4 week Time Point

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.